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ABSTRACT: Cys-loop receptors are the site of action of many therapeutic drugs. One of
these is the smoking cessation agent varenicline, which has its major therapeutic effects at
nicotinic acetylcholine (nACh) receptors but also acts at 5-HT3 receptors. Here, we report
the X-ray crystal structure of the 5-HT binding protein (5-HTBP) in complex with
varenicline, and test the predicted interactions by probing the potency of varenicline in a
range of mutant 5-HT3 receptors expressed in HEK293 cells and Xenopus oocytes. The
structure reveals a range of interactions between varenicline and 5-HTBP. We identified
residues within 5 Å of varenicline and substituted the equivalent residues in the 5-HT3
receptor with Ala or a residue with similar chemical properties. Functional characterization
of these mutant 5-HT3 receptors, using a fluorescent membrane potential dye in HEK cells
and voltage clamp in oocytes, supports interactions between varenicline and the receptor that are similar to those in 5-HTBP.
The structure also revealed C-loop closure that was less than in the 5-HT-bound 5-HTBP, and hydrogen bonding between
varenicline and the complementary face of the binding pocket via a water molecule, which are characteristics consistent with
partial agonist behavior of varenicline in the 5-HT3 receptor. Together, these data reveal detailed insights into the molecular
interaction of varenicline in the 5-HT3 receptor.
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The 5-HT3 receptors belong to the Cys-loop family of
pentameric ligand-gated ion channels, a family that also
includes nicotinic acetylcholine (nACh), GABA, and glycine
receptors.1 They play important roles in fast neurotransmission
in the central and peripheral nervous systems. There are five 5-
HT3 receptor subtypes (5-HT3A−5-HT3E). Subunits of 5-HT3A
can assemble to form homopentamers, but the other subtypes
must coassemble with 5-HT3A subunits to form functional
receptors. However, it is as yet unclear what effect subunits 5-
HT3C-5-HT3E have on the receptor function.
2,3
Varenicline is a high affinity partial agonist of the α4β2 nACh
receptor in clinical use for smoking cessation.4 It is also a full
agonist at the α7 nACh receptor.5 There is considerable overlap
between compounds that act at α7 nACh and 5-HT3
receptors,6 and recently, we have shown that varenicline is
also a high affinity agonist at the human 5-HT3 receptor.
7 5-
HT3 receptors are located in the chemoreceptor trigger zone in
the area postrema and in the gastrointestinal tract, where they
have roles in regulating gut motility and the emesis reflex.8
Antagonists of 5-HT3 receptors, such as ondansetron and
palonosetron, are in clinical use as antiemetics to treat
postoperative nausea and vomiting and chemotherapy-induced
nausea and vomiting.9 Nausea is a common adverse effect
reported from patients receiving varenicline,4 and it is likely
that this is due to its actions at the 5-HT3 receptor. The design
of improved smoking cessation drugs that do not have such
cross-reactivity at the 5-HT3 receptor would clearly be of
benefit.
For this aim to be achieved, further information is needed
about the structure−activity relationships of varenicline binding
to different receptors. Here, we present the structure of
varenicline bound to 5-HTBP, an acetylcholine binding protein
(AChBP) from Aplysia californica (Ac) engineered to bind 5-
HT with high affinity.10 This protein carries the mutations
S92E, V140L, K141T, and Q55R (A1B2D1R) and displays
affinities for the 5-HT3 receptor antagonist granisetron and for
5-HT that are 21- and 4.3-fold higher than for native AChBP,
respectively. We have also performed a thorough mutagenesis
study on the human 5-HT3 receptor of residues predicted to be
near the ligand-binding site, characterizing these mutants both
in HEK293 cells using a fluorescent membrane potential dye
and in oocytes using two-electrode voltage clamp electro-
physiology. The data suggest that 5-HTBP is a good structural
model for examining ligand binding interactions, and functional
experiments on the 5-HT3 receptors yield additional
information on binding modes that cannot readily be
ascertained from structural information.
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■ RESULTS AND DISCUSSION
X-ray Crystal Structure of Varenicline-Bound 5-HTBP.
Several crystals were obtained from crystallization screens. One
of these crystals diffracted to a resolution of 2.3 Å, and a
complete diffraction data set was collected, which allowed for
the determination of the three-dimensional structure of 5-
HTBP in complex with varenicline. The crystal belongs to the
space group P41212, and the crystallographic unit cell has the
dimensions 72.8 Å (a), 72.8 Å (b), 479.22 Å (c), 90° (α), 90°
(β), 90° (γ) and contains one pentamer per asymmetric unit.
The electron density map was of excellent quality and
difference density could be clearly observed for varenicline in
all five orthosteric ligand binding sites (Figure S1, Supporting
Information). The orientation of varenicline in this structure is
similar to that in the two structures of varenicline bound to
AChBP11,12 (Figure S2, Supporting Information). In these
structures, however, varenicline is slightly further away from the
principal binding face.
Varenicline Interactions at the Principal Binding Face.
Varenicline is located at the interface between two subunits and
has interactions on the principal face with aromatic residues,
which are conserved within the Cys-loop family. The 5-HTBP−
varenicline structure shows hydrogen bonds between the
benzazepine nitrogen of varenicline and the hydroxyl of Y91
(loop A) and the backbone carbonyl of W145 (loop B), and
one a pyrazine nitrogen hydrogen bonds to Y193 (loop C)
(Figure 1). The equivalent of these and other residues within 5
Å of bound varenicline were mutated in the 5-HT3 receptor to
verify the orientation of varenicline; substitutions were made to
residues N128 in loop A, W183 and L184 in loop B, and F226,
M228, E229, and Y234 in loop C. The parameters obtained
from concentration response curves determined from these
mutant receptors expressed in HEK cells are in Tables 1 and 2,
and typical responses and curves are shown in Figure 2.
The functional data from 5-HT3N128A receptors support
the presence of a hydrogen bond here, as observed in 5-HTBP,
because the EC50 in this mutant is increased 10-fold compared
to that of the WT. However, an even larger change in the
varenicline EC50 was seen with N128Q, which was unexpected
as this residue also has hydrogen bonding ability. We propose
that this larger amino acid is positioned incorrectly and is
unable to form an H bond. Examination of the published 5-HT3
receptor structure13 reveals that N128 is probably too far from
the center of the binding site to form a hydrogen bond with
smaller ligands, but this structure is in an unbound (apo) state
and thus movements induced by agonist binding could bring
N128 within hydrogen bonding distance. Such movement
would be consistent with previous studies that show this
residue is important for gating but not binding.14
The Trp residue in loop B forms cation-π interactions with
various agonists in a number of Cys-loop receptors (including
5-HT and 5-HT3
15). In 5-HTBP, we observe such an
interaction between this residue and the protonated benzaze-
Figure 1. Varenicline bound to 5-HTBP. (A) Location of varenicline (green) at the interface between two subunits in the orthosteric 5-HTBP
binding site. (B) Alignment of 5-HTBP, AChBP, and the extracellular domain of the 5-HT3A receptor subunit showing the approximate location of
the A−E binding loops. The residues mutated in this study are highlighted in purple, and the residues that differ between 5-HTBP and AChBP in
yellow. (C) The 5-HTBP binding pocket showing the orientation of varenicline (green) and nearby residues on the principal (blue) and
complementary (magenta) faces. The corresponding 5-HT3 receptor residues are in parentheses. (D) Hydrogen bonds are present between
varenicline and residues Y91, Y193, and W145 on the principal face and residues I104 and I116 on the complementary face via a water molecule.
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pine nitrogen of varenicline. The same interaction in 5-HT3
receptors is supported by a lack of function in 5-HT3W183A
receptors and is also consistent with data from varenicline
studies at the α4β2 nACh receptor,16 although varenicline does
not participate in a cation-π interaction with the TrpB residue
in the α7 nACh receptor.17 Another important loop B residue is
L184. Substitution of this residue to Ile resulted in an ∼10 fold
increase in EC50 with receptors expressed in HEK cells, but no
response was observed when we substituted this residue with
Ala. We did, however, observe responses in oocytes (Tables 3
and 4), which revealed a 46-fold increase in EC50 and a
decrease in Rmax/Rmax,5‑HT from 0.73 to 0.26 compared to those
of WT receptors (Figure 3). A previous study has shown that a
backbone L184 mutation causes partial loss of function and
converts the partial agonist mCPBG into an antagonist.18 There
is also increasing evidence that loop B is important for the
structure rather than the function of the receptor.19 We
therefore suggest that the role of L184 may be to define the
correct structure of the binding site.
The data show that the aromatic rings of the loop C residues
F226 and Y234 are important. Conservation of aromaticity in
the 5-HT3F226Y receptor had little effect on the EC50, whereas
a non-aromatic residue ablated agonist-gated currents, suggest-
ing a critical hydrophobic interaction. The important role of
Y234 has been shown in many studies, and the data were
similar here. Both an aromatic and a hydroxyl group play a role:
removal of the former in 5-HT3Y234A receptors ablated
function, and removal of the latter in 5-HT3Y234F receptors
increased the EC50. In 5-HTBP, the equivalent residue forms a
hydrogen bond with varenicline, and we propose a similar role
here. In the α7 nACh receptor, however, the residue equivalent
to Y234 (TyrC2) is not important for binding varenicline
(although it is involved in the binding of ACh and
epibatidine).17,20 In the previously reported varenicline-bound
AChBP structures (4AFG11 and 4AFT12), varenicline is further
away from this residue; a H bond is only predicted in one of the
five binding sites for Ac-AChBP (4AFT) and may occur via a
bridging water molecule in one of the Capitella telata−AChBP
sites (Figure S2, Supporting Information). Thus, it seems that
varenicline may have different interactions with different
receptors.
Table 1. Concentration Response Parameters of 5-HT
Obtained from HEK Cells
loop mutant 5-HT pEC50
a (M) 5-HT EC50 (μM) n
WT 6.51 ± 0.03 0.31 5
A N128
N128A 5.47 ± 0.10b 3.4 4
N128Q 4.53 ± 0.02b 29 4
B W183
W183A 3.88 ± 0.05b 130 4
W183Y 4.60 ± 0.03b 25 5
B L184
L184A NRc NRc 6
L184I 5.56 ± 0.05b 2.8 4
C F226
F226A 4.18 ± 0.05b 170 6
F226Y 5.72 ± 0.06b 1.9 7
C M228
M228A 5.03 ± 0.04b 9.4 4
M228C NRc NRc 6
C E229
E229A 5.63 ± 0.04b 2.3 6
E229D 6.58 ± 0.05 0.27 3
C Y234
Y234A NRc NRc 6
Y234F 5.89 ± 0.03b 1.3 4
Y234S NRc NRc 6
D W90
W90A NRc NRc 6
W90Y 5.66 ± 0.05b 2.2 5
D R92
R92A 6.06 ± 0.04b 0.87 4
R92Q 4.82 ± 0.04b 15 4
D Y94
Y94A 7.24 ± 0.03b 0.058 5
Y94F 6.84 ± 0.04 0.14 6
Y94S 7.03 ± 0.06b 0.093 6
S114
S114A 6.31 ± 0.05 0.48 7
S114T 5.87 ± 0.27b 1.4 3
E Y141
Y141A NRc NRc 6
Y141F 6.83 ± 0.03 0.15 3
E Y143
Y143A NRc NRc 6
Y143F 4.98 ± 0.09b 11 4
Y143S 4.35 ± 0.03b 45 3
E Q151
Q151A 6.13 ± 0.06 0.75 4
Q151N 6.34 ± 0.03 0.45 3
E Y153
Y153A 4.73 ± 0.03b 19 3
Y153F 5.54 ± 0.03b 2.9 3
Y153S 5.32 ± 0.06b 4.8 3
aData = mean ± SEM. bSignificantly different (p < 0.05) than that of
WT 5-HT3A receptors.
cNR = no response at 100 mM 5-HT.
Table 2. Varenicline Concentration Response Parameters







WT 6.38 ± 0.02 0.42 5
A N128 N128A 5.36 ± 0.05b 4.4 3
N128Q 4.58 ± 0.03b 26 3
B W183 W183A NRc NRc 6
W183Y 4.43 ± 0.04b 38 5
B L184 L184A NRc NRc 6
L184I 5.45 ± 0.04b 3.6 5
C F226 F226A 4.36 ± 0.12b 44 3
F226Y 5.99 ± 0.05b 1.0 3
C M228 M228A 4.53 ± 0.04b 30 3
M228C NRc NRc 6
C E229 E229A 5.38 ± 0.18b 4.2 3
E229D 5.98 ± 0.05b 1.1 3
C Y234 Y234A NRc NRc 6
Y234F 5.96 ± 0.04b 1.1 4
Y234S NRc NRc 6
D W90 W90A NRc NRc 6
W90Y 5.54 ± 0.03b 2.9 4
D R92 R92A 6.49 ± 0.06 0.39 4
R92Q 5.19 ± 0.03b 6.4 4
D Y94 Y94A 6.89 ± 0.02b 0.13 5
Y94F 6.43 ± 0.02 0.37 5
Y94S 6.82 ± 0.04b 0.15 6
S114 S114A 6.16 ± 0.05 0.95 3
S114T 5.36 ± 0.05b 4.3 4
E Y141 Y141A NRc NRc 6
Y141F 6.56 ± 0.07 0.28 4
E Y143 Y143A NRc NRc 6
Y143F SRd SRd 6
Y143S SRd SRd 6
E Q151 Q151A 6.22 ± 0.05 0.61 3
Q151N 5.67 ± 0.06b 2.1 4
E Y153 Y153A 5.03 ± 0.04b 9.4 3
Y153F 5.50 ± 0.06b 3.2 3
Y153S 5.38 ± 0.04b 4.2 3
aData = mean ± SEM. bSignificantly different (p < 0.05) than that of
WT 5-HT3A receptors.
cNR = no response at 100 mM varenicline dSR
= responses too small to obtain parameters.
ACS Chemical Neuroscience Research Article
DOI: 10.1021/cn500369h
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
C
Varenicline Interactions at the Complementary Bind-
ing Face. The structure revealed hydrogen bonds via a water
molecule to the backbone OH of I104 and NH of I116 (loop
E), and Y53 forms part of the aromatic box that surrounds
varenicline. To probe interactions with these and other residues
in the 5-HT3 receptor, we mutated W90, R92, and Y94 in loop
D, S114 (not in a binding loop), and Y141, Y143, Q151, and
Y153 in loop E, all of which are within 5 Å of varenicline.
Of the loop D residues, W90 (equivalent to 5-HTBP Y53)
appears to be the most important for functional responses to 5-
HT and varenicline. W90 has been previously investigated in
mouse 5-HT3 receptors, and its aromatic group is essential for
binding.21 Here, we show that substitution with Tyr, which has
only a small effect on EC50, significantly increases the efficacy of
varenicline, making it a full agonist (Figure 3, Table 4). In the
α4β2 nACh receptor, mutation of the equivalent Trp residue
also increased efficacy, in this case from 15 to 125%.11 A
different effect was observed in the α7 nACh receptor, where
the equivalent mutation causes the EC50 of varenicline to
increase much more than it does for ACh.17 These agonist-
specific effects at multiple receptors indicate that this residue
may be an important determinant of affinity and efficacy across
the superfamily, even though it may interact differently with
different ligands.
Substitution of the loop E residues Y141, Y143, and Y153
causes large changes in EC50 or even ablates function. Of these
residues, Y143 appears to play the biggest role as mutating this
residue in the 5-HT3 receptor has large effects on both the EC50
and the Rmax of varenicline, which is only 13% in Y143F mutant
receptors. Previously, we suggested that a hydrogen bond
formed by this residue was essential for receptor gating.22 With
the benefit of the recent high-resolution structure of the 5-HT3
receptor,13 we can see that the Y143 hydroxyl does indeed form
Figure 2. HEK cell data. (A) Typical traces from HEK cells transfected
with WT 5-HT3 receptor cDNA, loaded with membrane potential dye,
and stimulated at 20 s with various concentrations of varenicline. F =
arbitrary fluorescent units. (B) Concentration−response curves
constructed from FlexStation responses to 5-HT (squares, filled
line) and varenicline (circles, dashed line). Data = mean ± SEM, n = 4.










WT 5.65 ± 0.03 2.2 5
L184A 4.12 ± 0.03b 76 5 40
W90Y 4.97 ± 0.04b 11 3 5
Y143F 4.78 ± 0.10b 17 4 7.7
Y143S 4.22 ± 0.09b 60 4 27
Y153F 4.66 ± 0.04b 22 4 10
aData = mean ± SEM. bSignificantly different (p < 0.05) than that of
WT 5-HT3A receptors.
Table 4. Varenicline Concentration Response Parameters Obtained from Oocytes
mutant varenicline pEC50
a (M) varenicline EC50 (μM) varenicline fold change (EC50,mut/EC50,WT) varenicline efficacy (Rmax/Rmax,5‑HT)
WT 5.18 ± 0.08 6.6 0.73 ± 0.05
L184A 3.71 ± 0.03b 193 46 0.26 ± 0.03b
W90Y 4.42 ± 0.05b 38 5.8 0.92 ± 0.05b
Y143F 4.01 ± 0.07b 97 15 0.13 ± 0.01b
Y143S 3.85 ± 0.10b 142 22 0.33 ± 0.04b
Y153F 4.55 ± 0.05b 28 4.2 0.76 ± 0.04
aData = mean ± SEM. bSignificantly different (p < 0.05) than that of WT 5-HT3A receptors.
Figure 3. Concentration response curves for WT and mutant 5-HT3
receptors expressed in oocytes. Concentration response curves for (A)
5-HT3A L184A and (B) 5-HT3A W90Y mutant receptors (gray lines)
compared to WT 5-HT3A receptors (black lines) for 5-HT (solid lines)
and varenicline (dashed lines) reveal differences in EC50 and Rmax/
Rmax,5‑HT. Data = mean ± SEM, n = 3−6.
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hydrogen bonds to D189 and T186 backbone atoms across the
binding interface (Figure 4). Because both of these residues
have been previously identified as important for receptor
function,23,24 it seems likely that a network of hydrogen bonds
in this region are critical for receptor gating transitions. This
network may also involve Y141, which forms hydrogen bonds
with the backbone of V122, also across the interface, although
the hydroxyl group of this residue appears to be less critical.22
The hydroxyl group of Y153 is also important; its removal
through the Y153F mutation caused 4−10 fold changes in
EC50. The structure of the 5-HT3 receptor
13 shows this group
forming hydrogen bond interactions with other residues (Q151,
R92, and Y94; Figure 4) on the complementary face. The
residue equivalent to Y153 has been extensively studied in
AChBP and in nACh receptors. In AChBP, many structures
with bound ligands show direct or water-mediated hydrogen
bonds to the backbone NH of this residue, including the
varenicline-bound Ct-AChBP structure11 (Figure S2B, Support-
ing Information), and experimental evidence for such an
interaction with the backbone NH of the equivalent residue in
α4β2 nACh receptors has been demonstrated using unnatural
amino acid mutagenesis.25 In the α7 nACh receptor, the
equivalent mutation shows that the EC50 for varenicline
increases greater than 10-fold compared to that of ACh.17
Thus, different interactions with this residue in different
receptors likely contribute to drug selectivity and the observed
differences in efficacy.
Possible Explanations for the Partial Agonist Behav-
ior of Varenicline. There is substantial evidence that agonists
and antagonists induce different conformational changes in the
region of the C-loop with agonists causing C-loop closure
around the bound ligand.26,27 There is also increasing evidence
that partial agonists are unable to achieve the same extent of C-
loop closure seen with full agonists,28 although there do appear
to be some exceptions.12,26 In the varenicline-bound structure
presented here, there appears to be a small increase in the
C188−W145 distance compared to that of the 5-HT bound
structure. The distance between the γ-sulfur of C188 and the
carbonyl oxygen of W145 was found to be 7.34 Å (an average
from 5 binding sites) compared to an average distance of 6.89 Å
for the 10 binding sites in the 5-HT-bound 5-HTBP structure
(PDB: 2YMD), indicating that the C-loop in 5-HTBP contracts
more fully over 5-HT than varenicline (although we cannot
show statistical significance here due to errors associated with
the resolution and R-factor). A similarly increased distance has
been observed for the varenicline-bound relative to the ACh-
bound AChBP structure.11 This intermediate level of closure of
the C-loop could provide an explanation for the partial agonism
achieved by this drug at the 5-HT3 receptor. It may be,
however, that the partial agonism is due to differences in
interactions with the complementary face; Rohde et al.29 did
not observe large differences in the C188−W145 distances of a
range of structures of partial agonists with varying efficacies, but
did report a correlation between the strength of interactions
with residues on the complementary face and the degree of
efficacy. Thus, it may be that the difference between water-
mediated and direct hydrogen bonds to complementary face
residues with varenicline and 5-HT, respectively, results in the
partial agonist activity of the former.
■ CONCLUSIONS
In conclusion, we show here a high resolution structure of 5-
HTBP in complex with varenicline. Substitution and functional
characterization of 5-HT3 receptor residues that are equivalent
to those observed in the 5-HTBP binding site suggest that the
orientation of varenicline is similar in 5-HT3 receptors, where it
is a reasonably potent albeit a partial agonist. Differences in the
extent of C-loop closure and/or differences in interactions with
the complementary face residues could explain this partial
agonist activity.
■ METHODS
Protein Expression and Crystallization. 5-HTBP was expressed
and purified as previously described.10 A stock solution of varenicline
tartrate (Sigma) was made in water at a concentration of 500 mM and
mixed with 6 mg/mL 5-HTBP to yield a final varenicline
concentration of 5 mM. Cryoprotection of the crystals was achieved
by equilibration of the mother liquor in 5% increments of glycerol to a
final concentration of 30% glycerol, and crystals were immersed in
liquid nitrogen prior to X-ray diffraction data collection. The structure
was determined by molecular replacement using the published
structure of 5-HTBP as the template (PDB: 2YMD). After placing
the ligand into the electron density map, the model of the complex was
manually rebuilt and refined through iterative cycles in Coot and
Phenix. The final model has an Rwork value of 18.7% and Rfree value of
24.4%. Model validation was carried out in Molprobity, and the model
has a score of 1.75, which is in the 97th percentile for this resolution
range. Figures were prepared with Pymol.
Mutagenesis. All mutant receptors were created using Quik-
Change mutagenesis (Agilent). Residue numbering was altered to be
consistent with mouse 5-HT3 receptor numbering.
Cell Culture. Human embryonic kidney (HEK) 293 cells were
maintained on 90 mm tissue culture plates at 37 °C and 7% CO2 in a
humidified atmosphere. They were cultured in Dulbecco’s Modified
Eagle’s Medium/Nutrient Mix F12 (1:1) with GlutaMAX I media
(Life Technologies, Paisley, UK) containing 10% HyClone fetal calf
serum (GE Healthcare). For FlexStation studies, cells were transfected
using polyethylenimine (PEI; Polysciences). PEI (30 μL at 1 mg/mL),
cDNA (5 μL at 1 mg/mL; subcloned into pcDNA3.1), and DMEM (1
mL) were incubated for 10 min at room temperature, added dropwise
to a 70−90% confluent plate, and incubated for 2 days. Cells were then
transferred to poly-L-lysine (Cultrex)-coated 96-well plates and
allowed to adhere overnight before use.
FlexStation Analysis. The methods were used essentially as
described previously.30 In brief, fluorescent membrane potential dye
(Membrane Potential Blue kit, Molecular Devices) was diluted in flex
buffer (10 mM HEPES, 115 mM NaCl, 1 mM KCl, 1 mM CaCl2, 1
mM MgCl2, and 10 mM glucose, pH 7.4), and 100 μL was added to
each well of transfected cells. The cells were incubated at 37 °C for 45
min, and then fluorescence was measured in a FlexStation 3 microplate
Figure 4. The 5-HT3 receptor loop E region. Structural data from the
mouse 5-HT3A receptor structure (PDB: 4PIR) reveal a network of
hydrogen bonds involving the loop E aromatic residues Y141, Y143,
and Y153. Functional data show the importance of these residues for
proper functioning of the receptor.
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reader (Molecular Devices) at 2 s intervals for 200 s. Varenicline
tartrate (Tocris) or 5-HT (Sigma) was added to each well after 20 s.
The change in fluorescence (ΔF) was defined as Fmax (peak
fluorescence) − Fmin (baseline fluorescence). Data were normalized
to the maximum ΔF with the highest concentration of 5-HT.
Concentration−response data were fitted to the four-parameter
logistic equation using Prism (GraphPad Software Inc., San Diego,
CA).
Oocyte Maintenance and RNA Preparation. Xenopus laevis
oocytes were purchased from Ecocyte Bioscience (Austin, TX) and
stored in Barth’s solution (88 mM NaCl, 2.4 mM NaHCO3, 1 mM
KCl, 0.33 mM Ca(NO3)·4H2O, 0.41 mM CaCl2·2H2O, 0.82 mM
MgSO4·7H2O, and 5 mM Tris/HCl, pH 7.5) containing 2.5 mM
sodium pyruvate, 50 mM gentamicin, and 0.7 mM theophylline. RNA
was transcribed in vitro from Sph I-linearized plasmid cDNA template
using the mMessage mMachine T7 transcription kit (Ambion, Austin,
TX). Oocytes were injected with 5−20 ng of cRNA, and currents were
recorded 1−2 days post injection.
Electrophysiology. Oocytes were clamped at −60 mV using a
Roboocyte (Multi Channel Systems), an automated two-electrode
voltage clamp workstation. Concentration−response data for each
oocyte were normalized to the maximum current for that oocyte. The
mean and SEM for a series of oocytes were plotted against agonist
concentration and iteratively fitted to the four-parameter logistic
equation using Prism. Values are presented as mean ± SEM.
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